The precise mechanism remains unknown, but it is hypothesized that the interaction between HLA type II-expressing lymphoma cells and CD4+ T cells may contribute to tumor immunity in cALCL, potentially contributing to spontaneous tumor regression and improved outcomes. This evidence concerns the gene CD4 and lymphoma.